Computational design of drug candidates for influenza A virus subtype H1N1 by inhibiting the viral neuraminidase-1 enzyme
It is critical to seek potential alternative treatments for H1N1 infections by inhibiting neuraminidase-1 enzyme. One of the viable options for inhibiting the activity of neuraminidase- 1 is peptide drug design. In order to increase peptide stability, cyclization is necessary to prevent its digestio...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2014-06-01
|
| Series: | Acta Pharmaceutica |
| Subjects: | |
| Online Access: | http://www.degruyter.com/view/j/acph.2014.64.issue-2/acph-2014-0015/acph-2014-0015.xml?format=INT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832573343181570048 |
|---|---|
| author | Tambunan Usman Sumo Friend Parikesit Arli Aditya Dephinto Yonaniko Sipahutar Feimmy Ruth Pratiwi |
| author_facet | Tambunan Usman Sumo Friend Parikesit Arli Aditya Dephinto Yonaniko Sipahutar Feimmy Ruth Pratiwi |
| author_sort | Tambunan Usman Sumo Friend |
| collection | DOAJ |
| description | It is critical to seek potential alternative treatments for H1N1 infections by inhibiting neuraminidase-1 enzyme. One of the viable options for inhibiting the activity of neuraminidase- 1 is peptide drug design. In order to increase peptide stability, cyclization is necessary to prevent its digestion by protease enzyme. Cyclization of peptide ligands by formation of disulfide bridges is preferable for designing inhibitors of neuraminidase-1 because of their high activity and specificity. Here we designed ligands by using molecular docking, drug scan and dynamics computational methods. Based on our docking results, short polypeptides of cystein-arginine-methionine-tyrosine- -proline-cysteine (CRMYPC) and cysteine-arginine-aspargine- phenylalanine-proline-cysteine (CRNFPC) have good residual interactions with the target and the binding energy ΔGbinding of -31.7402 and -31.0144 kcal mol-1, respectively. These values are much lower than those of the standards, and it means that both ligands are more accessible to ligand-receptor binding. Based on drug scan results, both of these ligands are neither mutagenic nor carcinogenic. They also show good oral bioavailability. Moreover, both ligands show relatively stable molecular dynamics progression of RMSD vs. time plot. However, based on our metods, the CRMYPC ligand has sufficient hydrogen bonding interactions with residues of the active side of neuraminidase-1 and can be therefore proposed as a potential inhibitor of neuraminidase-1 |
| format | Article |
| id | doaj-art-318e2ea435044aa881051f33751b2b9b |
| institution | Kabale University |
| issn | 1330-0075 1846-9558 |
| language | English |
| publishDate | 2014-06-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Acta Pharmaceutica |
| spelling | doaj-art-318e2ea435044aa881051f33751b2b9b2025-02-02T04:37:56ZengSciendoActa Pharmaceutica1330-00751846-95582014-06-0164215717210.2478/acph-2014-0015acph-2014-0015Computational design of drug candidates for influenza A virus subtype H1N1 by inhibiting the viral neuraminidase-1 enzymeTambunan Usman Sumo Friend0Parikesit Arli Aditya1Dephinto Yonaniko2Sipahutar Feimmy Ruth Pratiwi3Department of Chemistry Faculty of Mathematics and Sciences Depok, University of IndonesiaDepartment of Chemistry Faculty of Mathematics and Sciences Depok, University of IndonesiaDepartment of Chemistry Faculty of Mathematics and Sciences Depok, University of IndonesiaDepartment of Chemistry Faculty of Mathematics and Sciences Depok, University of IndonesiaIt is critical to seek potential alternative treatments for H1N1 infections by inhibiting neuraminidase-1 enzyme. One of the viable options for inhibiting the activity of neuraminidase- 1 is peptide drug design. In order to increase peptide stability, cyclization is necessary to prevent its digestion by protease enzyme. Cyclization of peptide ligands by formation of disulfide bridges is preferable for designing inhibitors of neuraminidase-1 because of their high activity and specificity. Here we designed ligands by using molecular docking, drug scan and dynamics computational methods. Based on our docking results, short polypeptides of cystein-arginine-methionine-tyrosine- -proline-cysteine (CRMYPC) and cysteine-arginine-aspargine- phenylalanine-proline-cysteine (CRNFPC) have good residual interactions with the target and the binding energy ΔGbinding of -31.7402 and -31.0144 kcal mol-1, respectively. These values are much lower than those of the standards, and it means that both ligands are more accessible to ligand-receptor binding. Based on drug scan results, both of these ligands are neither mutagenic nor carcinogenic. They also show good oral bioavailability. Moreover, both ligands show relatively stable molecular dynamics progression of RMSD vs. time plot. However, based on our metods, the CRMYPC ligand has sufficient hydrogen bonding interactions with residues of the active side of neuraminidase-1 and can be therefore proposed as a potential inhibitor of neuraminidase-1http://www.degruyter.com/view/j/acph.2014.64.issue-2/acph-2014-0015/acph-2014-0015.xml?format=INTH1N1neuraminidase-1cyclic peptide disulfidemolecular dockingmolecular dynamics |
| spellingShingle | Tambunan Usman Sumo Friend Parikesit Arli Aditya Dephinto Yonaniko Sipahutar Feimmy Ruth Pratiwi Computational design of drug candidates for influenza A virus subtype H1N1 by inhibiting the viral neuraminidase-1 enzyme Acta Pharmaceutica H1N1 neuraminidase-1 cyclic peptide disulfide molecular docking molecular dynamics |
| title | Computational design of drug candidates for influenza A virus subtype H1N1 by inhibiting the viral neuraminidase-1 enzyme |
| title_full | Computational design of drug candidates for influenza A virus subtype H1N1 by inhibiting the viral neuraminidase-1 enzyme |
| title_fullStr | Computational design of drug candidates for influenza A virus subtype H1N1 by inhibiting the viral neuraminidase-1 enzyme |
| title_full_unstemmed | Computational design of drug candidates for influenza A virus subtype H1N1 by inhibiting the viral neuraminidase-1 enzyme |
| title_short | Computational design of drug candidates for influenza A virus subtype H1N1 by inhibiting the viral neuraminidase-1 enzyme |
| title_sort | computational design of drug candidates for influenza a virus subtype h1n1 by inhibiting the viral neuraminidase 1 enzyme |
| topic | H1N1 neuraminidase-1 cyclic peptide disulfide molecular docking molecular dynamics |
| url | http://www.degruyter.com/view/j/acph.2014.64.issue-2/acph-2014-0015/acph-2014-0015.xml?format=INT |
| work_keys_str_mv | AT tambunanusmansumofriend computationaldesignofdrugcandidatesforinfluenzaavirussubtypeh1n1byinhibitingtheviralneuraminidase1enzyme AT parikesitarliaditya computationaldesignofdrugcandidatesforinfluenzaavirussubtypeh1n1byinhibitingtheviralneuraminidase1enzyme AT dephintoyonaniko computationaldesignofdrugcandidatesforinfluenzaavirussubtypeh1n1byinhibitingtheviralneuraminidase1enzyme AT sipahutarfeimmyruthpratiwi computationaldesignofdrugcandidatesforinfluenzaavirussubtypeh1n1byinhibitingtheviralneuraminidase1enzyme |